Revolution Medicines launched to discover optimized analogues of natural products

Revolution Medicines has been created with a Series A financing of $45 million conducted by Third Rock Ventures. The company aims to discover and develop pharmaceutically optimized analogues of natural product drugs.

It will use synthesis methods developed at the University of Illinois at Urbana-Champaign under an exclusive license and will develop amphotericin B analogues originally discovered at the university. These analogues have minimal renal toxicity, while maintaining the potent antifungal activity of amphotericin B (Revolution Medicines News Release).